Codexis Inc. (NASDAQ:CDXS) shares fell 2.3% during trading on Friday . The company traded as low as $4.20 and last traded at $4.20, with a volume of 66,932 shares trading hands. The stock had previously closed at $4.30.

A number of brokerages recently commented on CDXS. Zacks Investment Research downgraded shares of Codexis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. HC Wainwright reaffirmed a “buy” rating on shares of Codexis in a research report on Tuesday, May 10th.

The company’s market cap is $172.96 million. The company’s 50-day moving average price is $4.21 and its 200 day moving average price is $3.83.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings data on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.09. During the same period in the prior year, the company earned ($0.14) EPS. The company had revenue of $16 million for the quarter, compared to the consensus estimate of $15.10 million. The firm’s revenue was up 166.7% compared to the same quarter last year. On average, analysts anticipate that Codexis Inc. will post ($0.20) EPS for the current fiscal year.

In other news, Director Bernard J. Kelley sold 12,643 shares of the firm’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $4.26, for a total value of $53,859.18. Following the transaction, the director now owns 234,906 shares of the company’s stock, valued at approximately $1,000,699.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivo Ventures Vii, Llc sold 50,000 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $4.27, for a total transaction of $213,500.00. The disclosure for this sale can be found here.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.